Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer. This is ...
Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial burden. Of these cases, 75% are non-muscle-invasive, which characterizes ...
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
The FDA approved a gemcitabine intravesical system (Inlexzo) for adults with non-muscle-invasive bladder cancer (NMIBC), the agency announced on Tuesday. The indication for the nucleoside metabolic ...
Neoadjuvant mitomycin C prior to TURBT reduced recurrence risk by 77%, possibly by preventing free-floating cancer cells dislodged during surgery from reimplanting and by increasing local exposure at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results